



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mapatumumab

Cat. No.:	HY-P99265
CAS No.:	658052-09-6
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer ^[1] .									
In Vitro	<p>Mapatumumab (0.01-100 µg/mL; 4 h) shows no growth inhibition to Pediatric Preclinical Testing Program (PPTP) cell lines^[1]. Mapatumumab (1-100 ng/mL; 24 h) shows significant potentiation of cytotoxicity and synergy when combined with (epirubicin) EPI for bladder cancer cells^[2].</p> <p>Mapatumumab (100 ng/mL; 12 h) induces significant cell apoptosis of T24, 253J and J82 cells with the combination of EPI (1 µg/mL)^[2].</p> <p>Mapatumumab (100 ng/mL; 6-24 h) significantly activates caspase-8, -9 and -3 with the combination of EPI (1 µg/mL)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Mapatumumab (10 mg/kg; i.p. for three times) controls tumor growth when combined with irradiation^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Colo205-xenograft-bearing NMRI (nu/nu) nude mice^[3]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8</td> </tr> <tr> <td>Result:</td> <td>Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1-5) showed a pronounced tumor regrowth-delay.</td> </tr> </table>		Animal Model:	Colo205-xenograft-bearing NMRI (nu/nu) nude mice ^[3]	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8	Result:	Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1-5) showed a pronounced tumor regrowth-delay.
Animal Model:	Colo205-xenograft-bearing NMRI (nu/nu) nude mice ^[3]									
Dosage:	10 mg/kg									
Administration:	Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8									
Result:	Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1-5) showed a pronounced tumor regrowth-delay.									

REFERENCES

- [1]. Smith MA, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. *Pediatr Blood Cancer*. 2010 Feb;54(2):307-10.
- [2]. Ahmed SM, et al. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. *Oncol Rep*. 2015 Feb;33(2):566-72.
- [3]. Marini P, et al. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. *Int J Radiat Oncol Biol Phys*. 2009 Sep 1;75(1):198-202.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA